Author:
Sabin Caroline A., ,Reiss Peter,Ryom Lene,Phillips Andrew N.,Weber Rainer,Law Matthew,Fontas Eric,Mocroft Amanda,de Wit Stephane,Smith Colette,Dabis Francois,d’Arminio Monforte Antonella,El-Sadr Wafaa,Lundgren Jens D.
Funder
the Highly Active Antiretroviral Therapy Oversight Committee
Publisher
Springer Science and Business Media LLC
Reference53 articles.
1. Sabin C, Worm S, Weber R, El-Sadr W, Reiss P, Thiebaut R, et al. Do thymidine analogues, abacavir, didanosine and lamivudine contribute to the risk of myocardial infarction? The D:A:D Study. Poster 957c. 15th Conference on Retroviruses and Opportunistic Infections, Boston, 3–6 February 2008.
2. D:A:D Study Group, Sabin CA, Worm SW, Weber R, Reiss P, El-Sadr W, et al. Use of nucleoside reverse transcriptase inhibitors and risk of myocardial infarction in HIV-infected patients enrolled in the D:A:D study: a multi-cohort collaboration. Lancet. 2008;371:1417–26.
3. Strategies for Management of Anti-Retroviral Therapy/INSIGHT; DAD Study Groups. Use of nucleoside reverse transcriptase inhibitors and risk of myocardial infarction in HIV-infected patients. AIDS. 2008;22:F17–24.
4. Martin A, Bloch M, Amin J, Baker D, Cooper DA, Emery S, et al. Simplification of antiretroviral therapy with tenofovir-emtricitabine or abacavir-lamivudine: a randomized, 96 week trial. Clin Infect Dis. 2009;49:1591–601.
5. Obel N, Farkas DK, Kronborg G, Larsen CS, Pedersen G, Riis A, et al. Abacavir and risk of myocardial infarction in HIV-infected patients on highly active antiretroviral therapy: a population-based nationwide cohort study. HIV Med. 2010;11:130–6.
Cited by
99 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献